Paxil
Phase 1Small molecule
TevaPaxil is one of 48 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 1.
1
Indications
5
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Elavil
AstraZenecaPhase 3
Crestor
AstraZenecaPhase 3
Daliresp
AstraZenecaPhase 3
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions2 trials
Major Depressive Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Paxil. EMBL-EBI & Wellcome Sanger Institute.
- [4]